# AB154 Combined With AB122 for Recurrent Glioblastoma

> **NCT04656535** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Yale University** · enrollment: 46 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Zimberelimab
- **DRUG:** Domvanalimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04656535
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-21
- **Primary completion:** 2026-03-17
- **Final completion:** 2026-12-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04656535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04656535, "AB154 Combined With AB122 for Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04656535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*